The Shotlee Journal
Browse Shotlee articles about Weight Loss.
Showing 9 / 1248 Weight Loss articles
New research suggests that GLP-1 receptor agonists, known for their roles in diabetes and weight management, may offer significant cardiovascular protection for patients undergoing complex procedures like TAVR and carotid artery stenting.
Many individuals experience remarkable initial success with Tirzepatide, only to find their progress unexpectedly stalling. This phenomenon, known as 'Plateau Panic,' is a growing concern. This article delves into why these plateaus occur, what they signify, and the advanced strategies available to help you regain momentum.
Eli Lilly Australia has announced that Mounjaro (tirzepatide) will not be listed on the Pharmaceutical Benefits Scheme (PBS) for Type 2 Diabetes, citing unsustainable funding conditions. This decision highlights ongoing challenges in accessing modern GLP-1 and GIP therapies.
The rise of GLP-1 medications is no longer a whisper; it's a culinary revolution. From shrinking appetites to evolving tastes, these powerful drugs are prompting a significant shift in how we eat out, forcing restaurants to adapt their offerings and dining strategies.
The emergence of GLP-1 receptor agonists has revolutionized obesity treatment, but concerns about weight regain upon discontinuation are significant. New research on duodenal mucosal resurfacing suggests a potential breakthrough in maintaining weight loss long-term.
Many users of GLP-1 medications like Ozempic and Wegovy report experiencing 'Ozempic personality,' a phenomenon characterized by emotional flattening and a reduced interest in formerly enjoyable activities. This article delves into what this means, potential causes, and how to navigate these changes.
A groundbreaking discovery using artificial intelligence has identified a naturally occurring molecule, BRP, that targets the brain's appetite center, potentially offering a new and improved alternative for weight management compared to current GLP-1 medications.
Eli Lilly has declined to list its highly effective GLP-1/GIP agonist, Mounjaro (tirzepatide), on the Pharmaceutical Benefits Scheme (PBS) in Australia, citing disagreements over pricing. This decision has significant implications for patients seeking access to this crucial medication for type 2 diabetes and increasingly, for weight management.
The world of biohacking is increasingly embracing peptides, but what's the reality behind the hype? This article delves into the science, the risks of unregulated substances, and the potential impact of regulatory changes on access to these compounds.
